Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with theKCNJ11/S225T, del226-232 mutation
- 14 June 2012
- journal article
- case report
- Published by Hindawi Limited in Pediatric Diabetes
- Vol. 13 (8), 656-660
- https://doi.org/10.1111/j.1399-5448.2012.00874.x
Abstract
Gain‐of‐function mutations of KCNJ11 can cause permanent neonatal diabetes mellitus, but only rarely after 6 months of age. Specific uncommon mutations KCNJ11 give rise to a syndrome defined as developmental delay, epilepsy, and neonatal diabetes (DEND ), or – more frequently – to a milder sub‐type lacking epilepsy, denoted as intermediate‐DEND (iDEND ). Our aim was to consider a possible monogenic etiology in a 12‐yr‐old boy with early onset diabetes and mild neurological features. We studied a subject diagnosed with diabetes at 21 months of age, and negative to type 1 diabetes autoantibodies testing. He had learning difficulties during primary school, and a single episode of seizures at the age of 10 yr. We performed direct DNA sequencing of the KCNJ11 gene with subsequent functional study of mutated channels in COSm6 cells. The patient's clinical response to oral glyburide (Glyb) was assessed. Motor coordination was evaluated before and after 6 and 12 months of Glyb therapy. Sequencing of the KCNJ11 gene detected the novel, spontaneous mutation S225T , combined with deletion of amino acids 226–232. In vitro studies revealed that the mutation results in a KATP channel with reduced sensitivity to the inhibitory action of ATP . Glyb improved diabetes control (hemoglobin A1c on insulin: 52 mmol/mol/6.9%; on Glyb: 36 mmol/mol/5.4%) and also performance on motor coordination tests that were impaired before the switch of therapy. We conclude that KCNJ11 /S225T , del226‐232 mutation caused a mild iDEND form in our patient. KCNJ11 should be considered as the etiology of diabetes even beyond the neonatal period if present in combination with negative autoantibody testing and even mild neurological symptoms.Keywords
This publication has 19 references indexed in Scilit:
- Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11Nature Clinical Practice Neurology, 2007
- Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glyburide in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2007
- An ATP-Binding Mutation (G334D) in KCNJ11 Is Associated With a Sulfonylurea-Insensitive Form of Developmental Delay, Epilepsy, and Neonatal DiabetesDiabetes, 2007
- Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 geneDiabetologia, 2006
- Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 MutationsNew England Journal of Medicine, 2006
- Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) geneDiabetologia, 2006
- Activating Mutations in Kir6.2 and Neonatal DiabetesDiabetes, 2005
- The C42R Mutation in the Kir6.2 (KCNJ11) Gene as a Cause of Transient Neonatal Diabetes, Childhood Diabetes, or Later-Onset, Apparently Type 2 Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 2005
- Activating Mutations in the Gene Encoding the ATP-Sensitive Potassium-Channel Subunit Kir6.2 and Permanent Neonatal DiabetesNew England Journal of Medicine, 2004
- Migraine and the benign partial epilepsies of childhood: evidence for an association.2000